All In Biotech

Drug Trial Radar · NCT07697443

Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects

Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3126 in Subjects With Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 12, 2026

Primary completion

Aug 2029

Study completion Aug 2030

Sponsor

Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study includes Phase I dose escalation and expansion and Phase II combination therapy. It uses a multicenter, open-label, non-randomized design to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3126 in breast cancer. Phase I dose escalation uses a Rolling 6 design after accelerated titration at the first dose, with dose decisions reviewed by the Safety Review Committee. Dose expansion includes two cohorts of approximately 20-60 participants each. The study also explores relationships between drug exposure and efficacy/safety, including concentration-QTc assessment using Holter electrocardiograms.

Conditions

  • Breast Cancer

Interventions

  • TQB3126Drug

    TQB3126 is a targeted protein degrader.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)Time frame: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
  2. Maximum Tolerated Dose (MTD)Time frame: From first dose of TQB3126 to the end of Cycle 1, approximately 35 days.
  3. Recommended Phase II Dose (RP2D)Time frame: Observation is expected to continue through Cycle 6 Day 28 throughout the study, around 6 months.
  4. Adverse Events (AEs)Time frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
  5. Serious Adverse Events (SAEs)Time frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
  6. Abnormal Incidence of Laboratory Test IndicatorsTime frame: From the time of first dose of TQB3126 to 28 days after the last dose or until the start of other anti-tumor therapy, whichever occurs first.
  7. Objective Response Rate (ORR)Time frame: From the date of first dose until the date of first documented disease progression, assessed up to approximately 3 years.
  8. Maximum Applicable Dose (MAD)Time frame: From the first dose of TQB3126 through completion of the Phase I dose-escalation assessment.

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Meizhou People's Hospital

    Meizhou, Guangdong, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.